NCT/Study#

NCT04142619 /

UCARTS1A

Phase I, open label dose-escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T-cells expressing anti-CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Multiple Myeloma

Phase I, open label dose-escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T-cells expressing anti-CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Multiple Myeloma

DISEASE GROUP:
Multiple Myeloma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: